PTGX Stock Analysis: Protagonist Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 9.339m USD | 12M Return: 148.9% | US74366E1029 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 72.1M
Qual. Beats: 0
Rev. Trend: -10.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Protagonist Therapeutics, Inc. is a US-based clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapeutics across multiple disease areas. Its pipeline includes Icotyde, an oral peptide for moderate-to-severe plaque psoriasis; Rusfertide, an injectable hepcidin mimetic in Phase 3 development for the rare blood disorder polycythemia vera; and earlier-stage candidates such as PN-881 (an oral IL-17 antagonist for immune-mediated skin diseases), as well as programs targeting obesity, atopic dermatitis, and asthma. The company was incorporated in 2006 and is headquartered in Newark, California.
The company operates within the biotechnology sub-industry of the healthcare sector, where peptide-based platforms represent a growing modality for addressing conditions traditionally served by biologics or small molecules. As a mid-cap US-listed entity trading on NASDAQ, PTGXs business model centers on advancing investigational candidates through clinical milestones, with future revenue typically dependent on successful development, regulatory approval, and commercialization-often through partnerships with larger pharmaceutical companies.
- Rusfertide Phase 3 data readout in polycythemia vera
- Icotyde oral psoriasis launch with Johnson & Johnson
- Obesity pipeline advances with PN-477 and amylinR agonists
| Net Income: 82.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 9.76 > 1.0 |
| NWC/Revenue: 273.0% < 20% (prev 271.1%; Δ 1.98% < -1%) |
| CFO/TA 0.15 > 3% & CFO 131.2m > Net Income 82.9m |
| Net Debt (-773.4m) to EBITDA (60.0m): -12.89 < 3 |
| Current Ratio: 21.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.0m) vs 12m ago 11.80% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 35.17% > 50% (prev 29.13%; Δ 6.04% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.87 (Total Current Assets 807.1m - Total Current Liabilities 37.2m) / Total Assets 885.5m |
| B: -0.34 (Retained Earnings -304.0m / Total Assets 885.5m) |
| C: 0.07 (EBIT TTM 58.3m / Avg Total Assets 801.8m) |
| D: 19.13 (Book Value of Equity 841.5m / Total Liabilities 44.0m) |
| Altman-Z'' = 25.16 = AAA |
| DSRI: 0.36 (Receivables 13.4m/28.0m, Revenue 282.0m/209.2m) |
| GMI: 0.99 (GM 98.58% / 99.57%) |
| AQI: 0.59 (AQ_t 0.08 / AQ_t-1 0.14) |
| SGI: 1.35 (Revenue 282.0m / 209.2m) |
| TATA: -0.05 (NI 82.9m - CFO 131.2m) / TA 885.5m) |
| Beneish M = -3.56 (Cap -4..+1) = AAA |
As of September 02, 2026, the stock is trading at USD 146.49 with a total of 534,120 shares traded. Over the past week, the price has changed by -2.72%, over one month by +10.74%, over three months by +54.33% and over the past year by +148.92%.
Current recommended Stop Loss: 136.20 (which is 7% or 1.7 ATR below the current price).
Protagonist Therapeutics has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy PTGX.
- StrongBuy: 5
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 170.4 | 16.3% |
P/E Trailing = 140.1262
P/E Forward = 37.3134
P/S = 33.1192
P/B = 11.4916
Revenue TTM = 282.0m USD
EBIT TTM = 58.3m USD
EBITDA TTM = 60.0m USD
Long Term Debt = 6.82m USD (estimated: total debt 9.22m - short term 2.40m)
Short Term Debt = 2.40m USD (from shortTermDebt, last quarter)
Debt = 9.22m USD (from shortLongTermDebtTotal, last quarter) (leases 9.22m already included)
Net Debt = -773.4m USD (calculated: Debt 9.22m - CCE 782.6m)
Enterprise Value = 8.57b USD (9.34b + Debt 9.22m - CCE 782.6m)
Interest Coverage Ratio = unknown (Ebit TTM 58.3m / Interest Expense TTM 0.0)
EV/FCF = 64.81x (Enterprise Value 8.57b / FCF TTM 132.2m)
FCF Yield = 1.54% (FCF TTM 132.2m / Enterprise Value 8.57b)
FCF Margin = 46.87% (FCF TTM 132.2m / Revenue TTM 282.0m)
Net Margin = 29.40% (Net Income TTM 82.9m / Revenue TTM 282.0m)
Gross Margin = unknown ((Revenue TTM 282.0m - Cost of Revenue TTM 1.23m) / Revenue TTM)
Tobins Q-Ratio = 9.67 (Enterprise Value 8.57b / Total Assets 885.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.22m)
Taxrate = 1.69% (1.43m / 84.3m)
NOPAT = 57.4m (EBIT 58.3m * (1 - 1.69%))
Current Ratio = 21.71 (Total Current Assets 807.1m / Total Current Liabilities 37.2m)
Debt / Equity = 0.01 (Debt 9.22m / totalStockholderEquity, last quarter 841.5m)
Debt / EBITDA = -12.89 (Net Debt -773.4m / EBITDA 60.0m)
Debt / FCF = -5.85 (Net Debt -773.4m / FCF TTM 132.2m)
Total Stockholder Equity = 689.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.34% (Net Income 82.9m / Total Assets 885.5m)
RoE = 12.03% (Net Income TTM 82.9m / Total Stockholder Equity 689.3m)
RoCE = 8.38% (EBIT 58.3m / Capital Employed (Equity 689.3m + L.T.Debt 6.82m))
RoIC = 6.86% (NOPAT 57.4m / Invested Capital 836.7m)
WACC = 3.91% (E(9.34b)/V(9.35b) * Re(3.91%) + D(9.22m)/V(9.35b) * Rd(0.0%) * (1-Tc(0.02)))
Discount Rate = 3.91% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.64 | Cagr: 5.02%
[DCF] Terminal Value 77.97% ; FCFF base≈94.1m ; Y1≈107.9m ; Y5≈158.8m
[DCF] Fair Price = 48.89 (EV 2.39b - Net Debt -773.4m = Equity 3.16b / Shares 64.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.26 | # QB: 0
Revenue Correlation: -10.82 | Revenue CAGR: -12.43% | SUE: -0.23 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.49 | Chg30d=+10.39% | Revisions=+0% | Analysts=10
EPS current Year (2026-12-31): EPS=4.75 | Chg30d=+12.73% | Revisions=+62% | GrowthEPS=+331.7% | GrowthRev=+1069.6%
EPS next Year (2027-12-31): EPS=0.06 | Chg30d=+110.83% | Revisions=+38% | GrowthEPS=-98.8% | GrowthRev=-62.4%
[Analyst] Revisions Ratio: +53% (up=10, down=2)